U.S. FDA Approves Japan Tobacco's Single-Dose Anti-HIV Drug
This article was originally published in PharmAsia News
Japan Tobacco's JTK-303 single-dose anti-HIV drug won approval by the U.S. FDA as applied by Gilead Sciences, the U.S. company with global rights to develop and market the drug except in Japan.
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.